美国前列腺穿刺前磁共振成像的应用趋势与因素
基于2009-2015年私人保险索赔数据,分析241,681名接受前列腺穿刺的男性,发现穿刺前MRI使用率从0.2%快速升至6.5%(P<.001),且更集中于大都市统计区(OR 1.90)和有既往阴性穿刺者(OR 4.63)。在2015年,近18%有既往阴性穿刺的男性接受了穿刺前MRI;有既往阴性穿刺者使用MRI引导穿刺的癌症检出率(25.2%)高于TRUS引导穿刺(19.7%,P=.010)。
要点
- 穿刺前MRI使用率从2009年0.2%升至2015年6.5%,但整体仍低。
- 大都市统计区男性接受MRI引导穿刺的 odds 更高(OR 1.90,95%CI 1.66-2.19)。
- 有既往阴性穿刺者更可能使用MRI引导(OR 4.63,95%CI 4.27-5.02)且癌症检出率更高。
核心结论
- 在美国接受前列腺穿刺的男性中,穿刺前MRI应用集中于城市地区和有既往阴性穿刺的患者,且在该人群中与优于传统TRUS-Bx的癌症检出相关。
研究设计与样本
- 基于私人保险索赔(2009-2015)的回顾性队列研究,纳入241,681名接受前列腺穿刺的男性(平均年龄57.5±5.4岁)。
主要发现
- MRI-Bx使用率从2009年0.2%上升至2015年6.5%(P<.001)。
- 大都市统计区男性接受MRI-Bx的OR为1.90(95%CI 1.66-2.19)。
- 有既往阴性穿刺者接受MRI-Bx的OR为4.63(95%CI 4.27-5.02)。
- 2015年,近18%有既往阴性穿刺的男性接受了穿刺前MRI。
- 有既往阴性穿刺者中,MRI-Bx的癌症检出率为25.2%,TRUS-Bx为19.7%(P=.010)。
临床怎么用
- 对于有既往阴性穿刺的男性,可考虑穿刺前MRI以提高癌症检出率。
- 城市地区穿刺前MRI的应用更普遍,需关注非城市地区的可及性差异。
局限性
- 基于私人保险索赔数据,可能不涵盖无保险或不同保险类型人群。
- 癌症诊断基于ICD-9-CM编码,可能存在编码偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess adoption of prebiopsy prostate magnetic resonance imaging (MRI) in the United States and to evaluate factors associated with magnetic resonance imaging-guided prostate biopsy (MRI-Bx) use. Prior reports have shown improved cancer detection with MRI-Bx vs transrectal ultrasound-guided methods (transrectal ultrasound-guided biopsy [TRUS-Bx]). Population-based trends of their use and outcomes have not been previously characterized. MATERIALS AND METHODS: Using private insurance claims (2009-2015), we identified men who underwent prostate biopsy. Exposures were biopsy year and geographic region defined by metropolitan statistical area. Outcomes included biopsy type (MRI-Bx, TRUS-Bx, or transperineal biopsy) based on procedure codes and cancer detection based on a new diagnosis for prostate cancer (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] 185). Hierarchical mixed-effects multivariable regression estimated odds of undergoing MRI-Bx. RESULTS: We identified 241,681 men (mean age 57.5 ± 5.4 years) who underwent biopsy. The use of MRI-Bx rose rapidly (0.2% in 2009 to 6.5% in 2015, P <.001). Overall, 3429 men underwent MRI before biopsy, more commonly in metropolitan statistical areas (odds ratio 1.90, 95% confidence interval 1.66-2.19). In 2015, nearly 18% of men with prior negative biopsy underwent a prebiopsy MRI. Patients with prior negative biopsies were over 4 times more likely to use MRI guidance (vs no prior biopsies, odds ratio 4.63, 95% confidence interval 4.27-5.02) and had a greater chance of cancer detection with MRI-Bx (25.2%) vs TRUS-Bx (19.7%, P = .010). CONCLUSION: Among men undergoing prostate biopsy, prebiopsy prostate MRI utilization was concentrated within urban areas and among patients with prior negative biopsies, where its use was associated with superior cancer detection compared with traditional TRUS-Bx.
引用
- Liu W, Patil D, Howard DH, et al. Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States. Urology. 2018. PMID: 29679601. doi:10.1016/j.urology.2018.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。